Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985623 | 0.85 | MMP12 (0.36) | NPY5RALDH1A1MAPTMAOBNPC1 | |
| SCHEMBL2756732 | 0.77 | ALDH1A1 (0.36) | NPY5RALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL2756727 | 0.76 | NPY5R (0.42) | NPY5RALDH1A1GAAMAPTADRA2A | |
| SCHEMBL16438128 | 0.74 | NPY5R (0.52) | NPY5RALDH1A1GAAMAPT | |
| SCHEMBL13746366 | 0.69 | NPY5R (0.41) | NPY5RMAPTADRA2AMAOBPIK3CA | |
| SCHEMBL2756725 | 0.69 | LMNA (0.36) | MAPTPIK3CAPIK3CBPIK3CGPIK3CD | |
| SCHEMBL31303039 | 0.68 | MAOB (0.64) | ALDH1A1MAOBNPC1CYP19A1GRM5 | |
| SCHEMBL768839 | 0.68 | MAOB (0.64) | ALDH1A1MAOBNPC1CYP19A1GRM5 | |
| SCHEMBL13204557 | 0.68 | MAOB (0.40) | ALDH1A1GAAMAPTHSD17B10ADRA2A | |
| SCHEMBL26714218 | 0.68 | MAOB (0.40) | ALDH1A1GAAMAPTHSD17B10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPY5R 4824/4885ALDH1A1 3492/4885GAA 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.